

Contents

Preface *XXI*

Acknowledgments *XXV*

A Note on Units *XVII*

Part I Overview of Health Physics: Radiation-Generating Devices, Characteristics, and Hazards 1

1 Introduction to Twenty-First Century Health Physics 3

1.1 Overview of Twenty-First Century Health Physics 3

1.2 Health Physics Issues, Challenges, and Opportunities 3

1.3 Forecast of Possible Future Issues 6

References 12

Part II Nuclear Fuel Cycle Issues 15

2 Nuclear Fuel Cycle 17

2.1 Overview 17

2.2 Basic Fuel Cycle Options 18

2.3 Overview of the Twentieth-Century Nuclear Fuel Cycle 18

2.3.1 Uranium Fuel Cycle 19

2.3.1.1 Uranium Ore and Chemical Processing 19

2.3.1.2 Overview of Existing Enrichment Technologies 20

2.3.1.3 Nuclear Fuel 24

2.3.1.4 Reactor Power Production 24

2.3.1.5 Spent Fuel 25

2.3.1.6 Fuel Reprocessing 25

2.3.1.7 Radioactive Waste 29

2.3.2 Thorium Fuel Cycle 31

2.4 Twenty-First-Century Changes and Innovations 31

2.4.1 Advanced Uranium Enrichment Technologies 32

2.4.1.1 Advanced Centrifuge Technology 32

2.4.1.2 Laser Isotope Separation 33

2.4.2 Power Reactors 40

2.4.2.1	Generation III Reactors	40
2.4.2.2	Generation IV Reactors	45
2.4.2.3	Small Modular Reactors	61
2.4.2.4	Health Physics Hazards	64
2.5	Nuclear Proliferation	75
2.5.1	Advanced Centrifuge and Laser Enrichment	75
2.5.1.1	Advanced Centrifuge	76
2.5.1.2	Laser Enrichment	76
2.5.2	Reactor Plutonium Production	77
2.5.3	Fuel Reprocessing	78
2.5.4	Nuclear Forensics	80
2.5.5	Nuclear Suppliers	81
2.6	Twentieth-Century Waste Disposal Options and Solutions	81
2.6.1	Boreholes	81
2.6.2	Deep Injection	82
2.6.3	Rock Melting	82
2.6.4	Subseabed Disposal	83
2.6.5	Disposal at Sea	83
2.6.6	Disposal in Ice Sheets	83
2.6.7	Disposal in Space	84
2.6.8	Surface Storage and Shallow Land Burial	84
2.6.9	Geologic Disposal	85
2.6.10	High-Level Waste Disposal Resolution	86
2.7	Twenty-First-Century Fuel Cycle Options	86
2.7.1	Advanced Fuel Reprocessing	86
2.7.2	Partitioning and Transmutation	88
2.7.2.1	PMA Burning in Generation IV Reactors	89
2.7.2.2	Accelerator Destruction of Actinides and Fission Products	89
2.7.2.3	Gamma-Ray Free Electron Lasers	91
2.7.3	Neutron Requirements for Various Fuel Cycle Options	91
2.7.4	PAT Health Physics Considerations	92
2.7.4.1	Criticality Safety	93
2.7.4.2	Limiting Radionuclides	93
	References	103

Part III Accidents and Nuclear Events 109

3	Nuclear Accidents and Radiological Emergencies	111
3.1	Overview	111
3.2	Design Considerations	111
3.2.1	Fission Product Barriers	112
3.2.1.1	Fission Product Releases	113
3.2.1.2	Fission Product Deposition	114
3.2.2	Accident Assumptions	114
3.2.3	Design Basis Assumptions	115

3.2.3.1	Fission Product Inventory	115
3.2.3.2	Release Fractions	116
3.2.3.3	Timing of Release Phases	116
3.2.3.4	Radionuclide Composition	117
3.2.3.5	Chemical Form	117
3.2.4	Design Basis Accidents	117
3.2.4.1	Spent Fuel Pool Accidents	121
3.2.4.2	Dry Fuel Storage Accidents	122
3.2.5	Beyond Design Basis Accidents	124
3.2.6	Other Events	129
3.2.7	Probabilistic Risk Assessment	129
3.2.8	INES Event Classification Scale	130
3.3	Major Reactor Accidents	131
3.3.1	Three Mile Island	132
3.3.1.1	TMI-2 Accident Sequence	132
3.3.1.2	Fission Product Releases	132
3.3.1.3	Issues Associated with the Event	133
3.3.2	Chernobyl	133
3.3.2.1	Issues Associated with the Event	135
3.3.3	Fukushima Daiichi	135
3.3.3.1	Reactor Accident	137
3.3.3.2	Spent Fuel Pools Inventory	139
3.3.3.3	Spent Fuel Pools Impacts	142
3.3.3.4	Issues Associated with the Event	142
3.4	Emergency Preparedness Programs	142
3.4.1	Emergency Classification	143
3.4.1.1	Unusual Event	144
3.4.1.2	Alert	145
3.4.1.3	Site Area Emergency	145
3.4.1.4	General Emergency	145
3.4.2	Protective Action Guides	146
3.4.3	Protective Actions	146
3.4.4	Protective Action Recommendation Considerations	148
3.4.4.1	Evacuation Criteria	148
3.4.4.2	Sheltering Criteria	149
3.4.4.3	Administration of Prophylactic Agents	149
3.4.5	Emergency Planning Zones	150
3.4.6	IAEA Evacuation Zone Issues	150
3.4.7	Reentry Criteria	150
3.4.8	Psychological Effects of Evacuation	151
3.5	Accident Phases	151
3.6	Emergency Preparedness Effectiveness	152
3.6.1	Criteria for Safe Use of Food, Water, and Land Following a Release of Radioactive Materials	153
3.6.2	Stakeholder Involvement	154

3.6.2.1	Stakeholder Groups	154
3.6.2.2	Stakeholders in the Decision Process	155
3.6.3	Dose Reconstruction	156
3.6.3.1	Essential Steps and Foundation Elements	156
3.6.3.2	Radiation Dose Estimation	157
3.6.3.3	Evaluation of Uncertainty	159
3.6.3.4	Categories of Dose Reconstruction	159
3.6.4	Remediation of Contaminated Areas	160
3.6.5	MARSSIM	162
3.7	Reprocessing Waste Tanks	162
3.7.1	Hanford Waste Tank Facility Background	163
3.7.2	Dominant Waste Tank Isotopes and Unit-Liter Doses	163
3.7.3	Dose Calculation Methods	164
3.7.4	Design Basis Accidents	165
3.7.4.1	Flammable Gas Accidents	166
3.7.4.2	Tank Failure Due to Excessive Loads	166
3.7.4.3	Mixing of Incompatible Materials	166
3.7.4.4	Waste Transfer Leak	166
3.7.4.5	Unplanned Excavation/Drilling	166
3.7.4.6	Natural Events	167
3.7.4.7	Aircraft Crashes into the Waste Tank	167
3.7.5	Beyond Design Basis Accidents	167
3.7.6	Accident Analysis Conservatism	167
3.8	Waste Isolation Pilot Plant Accident	169
	References	180
4	Nuclear Terrorist Events Including INDs and RDDs	187
4.1	Overview	187
4.2	Nuclear Weapons Types	188
4.2.1	Fission Weapons	188
4.2.2	Boosted Fission Weapons	189
4.2.3	Fusion Weapons	189
4.2.4	Clandestine Devices	190
4.3	Nuclear Event Types	190
4.3.1	Nuclear Weapons and Improvised Nuclear Devices	191
4.3.1.1	General Properties of Nuclear Explosions	192
4.3.1.2	Initial Nuclear Radiation	196
4.3.1.3	Delayed Nuclear Radiation and Fallout	198
4.3.1.4	Implications of IND Size	202
4.3.1.5	Medical Response Activities	203
4.3.1.6	HOTSPOT	203
4.3.2	Radiological Dispersal Devices	204
4.3.3	Radiation Exposure Devices	209
4.3.4	Deliberate Contamination of Food, Water, or Other Consumables	209

4.3.5	Dispersal of Radioactive Materials from Fixed Radiological or Nuclear Facilities or Materials in Transit	210
4.3.6	Health Physics Response and Medical Consequences of a Terrorist Event	210
4.4	Accident Assumptions	211
4.4.1	Accident Phases	211
4.4.2	Emergency Planning Zones	212
4.4.3	Protective Action Recommendations	213
4.4.4	Emergency Response Actions	218
4.4.4.1	Light Damage Zone	220
4.4.4.2	Moderate Damage Zone	220
4.4.4.3	Severe Damage Zone	220
4.4.4.4	Public Information Programs and Initial Actions	221
4.4.4.5	Subsequent Emergency Response Actions	222
4.4.5	Preplanned Evacuation Zones	223
4.4.6	Reentry and Recovery Considerations	224
4.4.7	Volunteers	225
4.5	Radiation Protection Considerations	226
4.5.1	Nuclides of Interest	227
4.5.2	External Dose Considerations	228
4.5.3	Internal Dose Considerations	228
4.5.3.1	Management of Contaminated Individuals	228
4.5.3.2	Internal Dose Determination	229
4.5.4	Emergency Screening of Contaminated Individuals	237
4.5.4.1	External Contamination	237
4.5.4.2	Internal Contamination	238
4.6	Mass Casualty Considerations	240
4.7	Stakeholder Involvement	240
4.8	Contamination Remediation	241
	References	253

Part IV Nuclear Medicine and Public Health 259

5	Nuclear Medicine	261
5.1	Overview	261
5.2	General Nuclear Medicine Categories	262
5.2.1	Established Imaging Approaches	262
5.2.1.1	X-Ray Imaging Radiography and Fluoroscopy	262
5.2.1.2	Diagnostic Radionuclide Administration	264
5.2.1.3	Computed Tomography	266
5.2.2	Established Therapy Applications	267
5.2.2.1	Therapeutic Radionuclide Administration	267
5.2.2.2	External Beam Therapy	268
5.2.2.3	Brachytherapy	268
5.2.2.4	Radioimmunotherapy	272

5.2.3	Targeted Delivery of Dose	272
5.2.3.1	Low-Energy Brachytherapy	273
5.2.3.2	Image-Guided Radiation Therapy	273
5.2.3.3	Intensity-Modulated Radiation Therapy	273
5.2.3.4	Stereotactic Radiosurgery and Stereotactic Body Radiotherapy	274
5.2.4	Source Security	275
5.3	Side Effects from Radiation Therapy	275
5.3.1	General Description	276
5.3.2	Second Primary Cancers and Cardiovascular Disease	276
5.3.3	Future Considerations	277
5.4	Emerging Therapy Approaches	277
5.4.1	Fundamental Physics Considerations	277
5.4.2	Dose Delivery Methods	278
5.4.3	RBE Considerations	281
5.4.4	Multimodal Therapy Options	281
5.4.5	Tracking Dose Profiles	282
5.5	Evolving, Emerging, and New Therapy Approaches	282
5.5.1	External Beam Proton Therapy	283
5.5.2	External Beam Heavy Ion Therapy	284
5.5.3	External Pion and Muon Beams	290
5.5.4	External Beam Antimatter Therapy	293
5.5.5	Alpha Radiopharmaceuticals	294
5.5.6	Neutron Therapy	295
5.5.7	Radionuclide Vascular Therapy	297
5.5.7.1	Tumor Vasculature	297
5.5.7.2	Current Radiological Efforts	297
5.5.7.3	Theoretical Approach	298
5.5.7.4	Other Candidate Microspheres	299
5.6	Nanotechnology	304
5.6.1	Principles of Nanomedicine	304
5.6.2	General Nanotechnology-Based Therapy Techniques	305
5.6.2.1	Nanotechnology Radiation Therapy	305
5.6.2.2	Nanomachines	306
5.6.2.3	Magnetic Fluid Hyperthermia Therapy	306
5.6.3	Specific Nanoparticle Applications	307
5.6.3.1	Nanoparticles Loaded with Radioactive Materials	307
5.6.3.2	Internal Radiation-Generating Devices	308
5.6.3.3	Hybrid Medical Imaging	324
5.6.3.4	Cherenkov Luminescence Imaging	326
5.6.3.5	Photodynamic Therapy	327
5.6.3.6	Low-Coherence Interferometry	327
5.6.3.7	Nonlinear Interferometric Vibrational Imaging	327
5.6.3.8	Optical Coherence Tomography	328
5.6.3.9	Personal Genomics	329
5.6.3.10	Second-Generation Nanotechnology	329

5.7	Other Considerations	330
	References	338
6	Public Radiation Exposures and Associated Issues	345
6.1	Overview	345
6.2	Public Radiation Exposures and Associated Effects	345
6.2.1	Ubiquitous Background Radiation	346
6.2.1.1	Cosmogenic Radionuclides	347
6.2.1.2	Primordial Radionuclides	347
6.2.1.3	Radon	347
6.2.1.4	Anthropogenic Radionuclides	347
6.2.1.5	Radiation from Space	348
6.2.1.6	Solar-Induced Disruptions and Radiation Effects	348
6.2.2	Medical Exposure	355
6.2.2.1	Trends in CT Medical Exposure	356
6.2.2.2	Mammography Doses	356
6.2.2.3	Dose from Emerging Techniques	356
6.2.3	Consumer Products and Activities	357
6.2.3.1	Source Control	359
6.2.4	Industrial, Security, Medical, Educational, and Research Activities	365
6.2.4.1	Nuclear Power Operations	365
6.2.4.2	Airport Scanners	365
6.2.5	Occupational Exposure	367
6.2.5.1	Definition of Radiation Workers	368
6.2.5.2	Aircrew Radiation Exposures	368
6.2.5.3	Morticians and Medical Examiners	369
6.3	Summary of Doses to the US Population	370
6.4	Public Dose Limits	370
6.5	Risk Communication	371
6.5.1	TMI-2 Accident	373
6.5.1.1	Enhanced Communications Organization	375
6.5.1.2	Off-Site Monitoring Network	375
6.5.2	Chernobyl	375
6.5.3	Fukushima Daiichi	376
6.6	Public Involvement in Nuclear Licensing	377
6.6.1	Emergency Response	378
6.6.2	Stakeholder Involvement	378
6.6.2.1	Incorporation of Nuclear Energy in a National Energy Plan	379
6.6.2.2	Development of Nuclear Regulation Legislation	379
6.6.2.3	Decisions to Build a Major Nuclear Facility	380
6.6.2.4	Emergency Planning Development and Implementation	380
6.6.2.5	Facility Releases of Radioactive Material	380
6.6.2.6	Environmental Restoration of Legacy Sites	381
6.6.2.7	Nuclear Facility Decontamination and Decommissioning	382

6.6.2.8	Radioactive Waste Management	382
6.6.2.9	Transportation of Radioactive Materials	382
6.6.2.10	Security of Nuclear Sites and Special Nuclear Material	383
6.6.3	Canadian Process for Licensing a High-Level Waste Facility	384
6.6.4	US Reactor Licensing Process	385
6.7	Litigation	386
6.8	Environmental Protection	386
6.8.1	Reference Animals and Plants	387
6.8.2	Derivation of Protective Measures	388
6.9	Unresolved Issues Associated with Major Reactor Accidents	389
6.9.1	Radiation Risk	389
6.9.2	Radiation Units Used to Quantify Radiation Dose	389
6.9.3	Internal Dose Assessment	390
6.9.4	Emergency Management Guidance	390
6.9.5	Emergency Medical Response	391
6.9.6	International Emergency Criteria	392
6.9.6.1	Protecting Rescuers and Volunteers	392
6.9.6.2	Public Evacuations	393
6.9.6.3	De-escalating from an Emergency Classification	394
6.9.6.4	Reentry into Evacuated Areas	394
6.9.6.5	Emergency Public Dose Limits	395
6.9.6.6	Emergency Dose Limits for Children and Fetuses	396
6.9.6.7	Public Dosimetry and Dose Monitoring	396
6.9.6.8	Environmental Contamination	396
6.9.6.9	Psychological Consequences	398
6.9.6.10	Public and Media Communications	398
	References	409

Part V Regulatory Issues, Limitations, and Challenges 415

7	Regulatory Considerations	417
7.1	Overview	417
7.2	Twentieth-Century Regulatory Challenges	418
7.2.1	Containment Fission Product Barrier	418
7.2.2	Emergency Core Cooling System Contention	419
7.2.3	Lyons High-Level Waste Disposal Facility	419
7.2.4	Transition from AEC to NRC	420
7.2.5	Browns Ferry Fire	420
7.2.6	Reactor Safety Study	421
7.2.7	TMI-2 Accident	421
7.2.8	Salem ATWS Events	423
7.2.9	Chernobyl	424
7.2.10	Towers Perrin Report	424
7.2.11	Millstone Safety Allegations	425
7.3	Twenty-First-Century Regulatory Challenges	426

7.3.1	11 September 2001 Attacks	426
7.3.2	Davis–Besse Reactor Vessel Head Erosion	427
7.3.3	Yucca Mountain High-Level Waste Repository	428
7.3.4	Fukushima Daiichi Accident	428
7.3.4.1	NRC Review	429
7.3.4.2	Japanese Diet Commission Review	430
7.3.4.3	FLEX Strategy	431
7.3.5	Waste Disposal	431
7.4	Proactive Vice Reactive Philosophy	432
7.5	Accident Analysis and Risk Assessment	433
7.5.1	Design Basis Accidents	433
7.5.2	Beyond Design Basis Accidents	434
7.6	Licensing Process and Technical Basis	435
7.6.1	Stakeholder Involvement	435
7.7	National and International Standards	436
7.7.1	Benefits of Standardization for Nuclear Safety	437
7.7.2	Benefits of Standardization for Regulators	438
7.7.3	Benefits for the Nuclear Industry	439
7.7.4	Future Directions	439
7.8	Accidents Affecting Multiple Nations	439
7.8.1	TMI-2	440
7.8.2	Chernobyl-4	442
7.8.3	Fukushima Daiichi	444
7.8.3.1	Protective Actions	445
7.8.3.2	Releases of Radioactive Material	447
7.9	Emergency Response	448
7.10	Emerging Issues	451
7.10.1	Public Dose Limit Considerations	451
7.10.1.1	Normal Conditions	452
7.10.1.2	Emergency Conditions	453
7.10.2	Radiation Worker Dose Limits	455
7.10.2.1	Normal Operations	456
7.10.2.2	Planned Special Exposures	456
7.10.2.3	Emergency Operations	457
7.10.3	Future Dose Limits	458
7.10.3.1	LNT Hypothesis	458
7.10.3.2	Challenges to the LNT Hypothesis	459
7.10.3.3	New Regulatory Options	460
7.10.4	Reactor Aging	462
7.10.5	Tritium Leakage	463
7.10.6	Reactor Safety	465
7.10.7	Nuclear Waste Management	465
7.10.8	Climate Change	467
7.10.8.1	Greenhouse Gases	468
7.10.8.2	Oxygen Isotopes	469

7.11	US Regulatory Improvements	471
7.11.1	US Regulatory Enhancements	472
7.11.1.1	State-of-the-Art Reactor Consequence Analyses	472
7.11.1.2	Risk-Informed Regulatory Framework	473
7.11.2	Nuclear Regulatory Options	474
7.11.2.1	General Options	474
7.11.2.2	Specific Options and Future Directions	476
7.11.2.3	Outlook	478
7.12	Future Power Reactor Directions and Challenges	478
	References	490

Part VI Solutions to Problems 497**Solutions** 499**Part VII Appendices 661**

A	Selected Data on Radionuclides of Health Physics Interest	663
A.1	Introduction	663
A.2	Alpha Decay	663
A.3	Beta Decay	663
A.4	Gamma Emission	668
A.5	Internal Conversion	668
A.6	Electron Capture	668
A.7	Positron Emission	668
A.8	Spontaneous Fission	668
	References	669
B	Production Equations in Health Physics	671
B.1	Introduction	671
B.2	Theory	671
B.3	Examples of Production Equations	674
B.3.1	Activation	674
B.3.2	Demineralizer Activity	675
B.3.3	Surface Deposition	675
B.3.4	Release of Radioactive Material into a Room	676
B.4	Alternative Derivation of the Production Equation	676
B.5	Conclusions	677
	References	677
C	Key Health Physics Relationships	679
C.1	Introduction	679
C.2	Notation and Terminology	679
C.3	Key Relationships	682
C.3.1	Activation	682

C.3.2	Activity	682
C.3.3	Attenuation	683
C.3.4	Duty Factor	683
C.3.5	External Dosimetry	683
C.3.6	Internal Dosimetry	684
C.3.7	Dispersion Relationships	684
C.3.8	Electromagnetic Relationships	684
C.3.9	Mechanics Relationships	686
C.3.10	Relationships	687
C.3.11	Production Equations	687
C.3.12	Quantum Mechanics	687
	References	688
D	Internal Dosimetry	689
D.1	Introduction	689
D.2	Overview of Internal Dosimetry Models	689
D.3	MIRD Methodology	691
D.4	ICRP Methodology	693
D.5	Biological Effects	693
D.6	ICRP 26/30 and ICRP 60/66/30 Terminology	696
D.7	ICRP 26 and ICRP 60 Recommendations	697
D.7.1	Calculation of Internal Dose Equivalents Using ICRP 26/30	698
D.7.2	Calculation of Equivalent and Effective Doses Using ICRP 60/66/30	699
D.8	ICRP 103/66/100 Methodology	701
D.8.1	Radiation Effects, Tissue Weighting Factors, and Radiation Weighting Factors	701
D.8.2	Sex Averaging	702
D.8.3	Assessment of Occupational Dose	703
D.9	Human Respiratory Tract Model (HRTM)	704
D.9.1	Absorption	705
D.9.2	Particle Sizes	705
D.9.3	Additional Model Details	706
D.10	Human Alimentary Tract Model (HATM)	706
D.10.1	Absorption to Blood	707
D.10.2	Dose Calculations	710
D.10.3	Model Dependence	710
	References	710
E	Health Physics-Related Computer Codes	713
E.1	Overview	713
E.2	Code Descriptions	713
E.2.1	CAP-88 (http://www.epa.gov/radiation/assessment/ CAP88/index.html)	713

- E.2.2 COMPASS (<http://orise.orau.gov/environmental-assessments-health-physics/resources/marssim.aspx>) 714
- E.2.3 COMPLY (<http://www.epa.gov/radiation/assessment/comply.html#download>) 714
- E.2.4 DCAL (<http://www.epa.gov/radiation/assessment/dcal.html#download>) 714
- E.2.5 DWUCK/CHUCK/MERCURY (<https://rsicc.ornl.gov/codes/psr/psr5/psr-546.html>) 715
- E.2.6 EGS Code System (<http://rcwww.kek.jp/research/egs/egs5.html>) 715
- E.2.7 ENDF (<http://www.nndc.bnl.gov/exfor3/endf00.htm>) 715
- E.2.8 FLUKA (<http://www.fluka.org/>) 716
- E.2.9 GENII-LIN (<http://www-rsicc.ornl.gov/codes/ccc/ccc7/ccc-728.html>) 716
- E.2.10 HOTSPOT (<http://www-rsicc.ornl.gov/codes/mis/mis0/mis-009.html>) 716
- E.2.11 IDD-SAM (www.bevelacquaresources.com) 716
- E.2.12 IMBA (www.hpa-radiationservices.org.uk/services/imba) 717
- E.2.13 ISO-PC (<https://rsicc.ornl.gov/codes/ccc/ccc6/ccc-636.html>) 717
- E.2.14 JENDL (<http://wwwndc.tokai-sc.jaea.go.jp/jendl/jendl.html>) 717
- E.2.15 LISE++ (<http://lise.nscl.msu.edu/lise.html>) 718
- E.2.16 MACCS2 (<http://www.nrc.gov/about-nrc/regulatory/research/comp-codes.html>) 718
- E.2.17 MARS (<http://www-ap.fnal.gov/MARS/>) 718
- E.2.18 MCNP (<http://mcnp-green.lanl.gov/index.html>) 718
- E.2.19 MCNPX (<http://mcnpx.lanl.gov/>) 719
- E.2.20 MICROSHIELD®(<http://www.radiationsoftware.com/mshield.html>) 719
- E.2.21 MICROSKYSHINE®(<http://www.radiationsoftware.com/mskyshine.html>) 719
- E.2.22 MIDAS (<http://www.absconsulting.com/midas.cfm>) 719
- E.2.23 MULTIBIODOSE (<http://www.multibiodose.eu/software.html>) 720
- E.2.24 OLINDA/EXM (<http://olinda.vueinnovations.com/olinda>) 720
- E.2.25 PRESTO (<http://www.epa.gov/radiation/assessment/presto.html>) 720
- E.2.26 RADTRAD (<http://www-rsicc.ornl.gov/codes/ccc/ccc8/ccc-800.html>) 720
- E.2.27 RASCAL (<http://www-rsicc.ornl.gov/codes/ccc/ccc7/ccc-783.html>) 721
- E.2.28 RESRAD (<http://web.ead.anl.gov/resrad/home2/>) 721
- E.2.29 SCALE 5 (<http://www-rsicc.ornl.gov/codes/ccc/ccc7/ccc-725.html>) 721
- E.2.30 SKYSHINE-KSU (<http://www-rsicc.ornl.gov/codes/ccc/ccc6/ccc-646.html>) 722

E.2.31	SPAR (http://www-rsicc.ornl.gov/codes/ccc/ccc2/ccc-228.html)	722
E.2.32	TRACE (http://www-rsicc.ornl.gov/codes/psr/psr4/psr-481.html)	722
E.2.33	VARSKIN (http://www-rsicc.ornl.gov/codes/ccc/ccc7/ccc-781.html)	723
E.2.34	VSM (http://www.doseinfo-radar.com/RADARSoft.html)	723
E.2.35	VSP (http://vsp.pnnl.gov/)	723
E.3	Code Utilization	723
E.4	Code Documentation	724
	References	724
F	Systematics of Charged Particle Interactions with Matter	727
F.1	Introduction	727
F.2	Overview of External Radiation Sources	727
F.2.1	Cancer Therapy	727
F.2.2	Accelerator Transmutation of High-Level Waste	728
F.2.3	Space Tourism	729
F.3	Tissue-Absorbed Dose from a Heavy Ion or Proton Beam	730
F.4	Determination of Total Reaction Cross-Section	730
F.5	Calculational Considerations	731
	References	731
G	Angular Absorbed Dose Dependence of Heavy Ion Interactions	733
G.1	Introduction	733
G.2	Basic Theory	733
G.3	Differential Scattering Cross-Section	734
G.4	Model Calculations	735
	References	735
H	Basis for Radiation Protection Regulations	737
H.1	Overview	737
H.2	Risk	737
H.3	Basic Epidemiology	739
H.4	Dose–Response Relationships	740
H.5	Risk Models	741
H.6	BEIR VII Uncertainties	742
H.7	Doubling Dose	743
H.8	Probability of Causation	743
H.9	Energy Employees Occupational Illness Compensation Program Act	745
H.10	Future Dose Limits	746
H.10.1	LNT Hypothesis	746
H.10.1.1	Arguments Supporting the LNT Hypothesis	747
H.10.1.2	Arguments against the LNT Hypothesis	747

H.10.2	Threshold Dose limits	748
H.10.3	Radiation Carcinogenesis	749
H.11	Future Regulations	749
	References	749

Index 753